465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Kapoun, A; O'Reilly, E; Cohn, A; Bendell, JC; Smith, L; Strickler, JH; Gluck, W; Liu, YW; Wallace, B; Tam, R; Cancilla, B; Brunner, A; Hill, D; Zhou, L; Dupont, J; Zhang, C; Wang, M

Published Date

  • November 2014

Published In

Volume / Issue

  • 50 /

Start / End Page

  • 152 - 152

Published By

International Standard Serial Number (ISSN)

  • 0959-8049

Digital Object Identifier (DOI)

  • 10.1016/s0959-8049(14)70591-x